Clinical Trial 16371

Tampa, FL 33609

Study Summary:

Are you a patient with moderate to severe plaque psoriasis? Have you treated your condition with adalimumab (Humira®) and has it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis.

Qualified Participants Must:

• 18 years of age or older
• Be diagnosed with moderate to severe plaque psoriasis
• Have lost a satisfactory response to adalimumab:
    i.e., currently taking adalimumab but it has stopped helping your psoriasis
    OR, you were taking adalimumab within the past 6 months and stopped
    because of loss of effectiveness
• Not be pregnant, breastfeeding, or planning to become pregnant for the duration of the study and for 4 weeks after the end of treatment

Qualified Participants May Receive:

Etanercept (Enbrel), study-related tests, exams, medical care related to the study from board-certified physicians and be reimbursed for expenses associated with study visits, such as travel expenses.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.